About Corcept Therapeutics (NASDAQ:CORT)
Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression. It is developing relacorilant that is in a Phase II trial to treat patients with Cushing's syndrome; abraxane in combination with relacorilant, which is in Phase I/II open label trial to treat solid tumors; and selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer. The company is also developing CORT118335 selective cortisol modulator, which is in Phase I/II open label trial for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:CORT
CUSIP21835210
Phone650-327-3270
Debt
Debt-to-Equity RatioN/A
Current Ratio4.20%
Quick Ratio4.05%
Price-To-Earnings
Trailing P/E Ratio39.98
Forward P/E Ratio18.32
P/E GrowthN/A
Sales & Book Value
Annual Sales$159.20 million
Price / Sales12.69
Cash Flow$0.4604 per share
Price / Cash38.21
Book Value$1.67 per share
Price / Book10.53
Profitability
EPS (Most Recent Fiscal Year)$0.44
Net Income$129.12 million
Net Margins81.11%
Return on Equity53.35%
Return on Assets42.53%
Miscellaneous
Employees136
Outstanding Shares114,830,000
Corcept Therapeutics (NASDAQ:CORT) Frequently Asked Questions
What is Corcept Therapeutics' stock symbol?
Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."
How were Corcept Therapeutics' earnings last quarter?
Corcept Therapeutics (NASDAQ:CORT) released its quarterly earnings results on Thursday, February, 22nd. The biotechnology company reported $0.17 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.19 by $0.02. The biotechnology company had revenue of $53.30 million for the quarter, compared to analyst estimates of $53.30 million. Corcept Therapeutics had a net margin of 81.11% and a return on equity of 53.35%. The firm's quarterly revenue was up 123.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.04 EPS. View Corcept Therapeutics' Earnings History.
When is Corcept Therapeutics' next earnings date?
What price target have analysts set for CORT?
5 Wall Street analysts have issued 12 month price objectives for Corcept Therapeutics' shares. Their forecasts range from $20.00 to $32.00. On average, they expect Corcept Therapeutics' stock price to reach $26.40 in the next twelve months. View Analyst Ratings for Corcept Therapeutics.
Who are some of Corcept Therapeutics' key competitors?
Some companies that are related to Corcept Therapeutics include Loxo Oncology (LOXO), FibroGen (FGEN), GW Pharmaceuticals (GWPH), Advanced Accelerator Application (AAAP), Blueprint Medicines (BPMC), Ligand Pharmaceuticals (LGND), Array BioPharma (ARRY), Tesaro (TSRO), Ultragenyx Pharmaceutical (RARE), Emergent BioSolutions (EBS), Amicus Therapeutics (FOLD), Ascendis Pharma (ASND), Evotec A.G. (EVTCY), Clovis Oncology (CLVS), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Acadia Pharmaceuticals (ACAD) and Akorn (AKRX).
Who are Corcept Therapeutics' key executives?
Corcept Therapeutics' management team includes the folowing people:
- Dr. Joseph K. Belanoff M.D., Co-Founder, CEO, Pres & Director (Age 61)
- Mr. Gary Charles Robb, CFO, Chief Accounting Officer & Sec. (Age 55)
- Dr. Robert S. Fishman M.D., ? F.C.C.P., Chief Medical Officer (Age 56)
- Dr. Hazel Hunt Ph.D., Sr. VP of Research
- Donald E. Laferle, Sr. VP
Has Corcept Therapeutics been receiving favorable news coverage?
Press coverage about CORT stock has been trending positive recently, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Corcept Therapeutics earned a coverage optimism score of 0.26 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 47.44 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of Corcept Therapeutics?
Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corcept Therapeutics' stock price today?
One share of CORT stock can currently be purchased for approximately $17.59.
How big of a company is Corcept Therapeutics?
Corcept Therapeutics has a market capitalization of $2.02 billion and generates $159.20 million in revenue each year. The biotechnology company earns $129.12 million in net income (profit) each year or $0.44 on an earnings per share basis. Corcept Therapeutics employs 136 workers across the globe.
How can I contact Corcept Therapeutics?
Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected]
MarketBeat Community Rating for Corcept Therapeutics (CORT)
MarketBeat's community ratings are surveys of what our community members think about Corcept Therapeutics and other stocks. Vote "Outperform" if you believe CORT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CORT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Corcept Therapeutics (NASDAQ:CORT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for Corcept Therapeutics in the last 12 months. Their average twelve-month price target is $26.40, suggesting that the stock has a possible upside of 50.09%. The high price target for CORT is $32.00 and the low price target for CORT is $20.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 2.60 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $26.40 | $25.00 | $23.3333 | $16.60 |
| Price Target Upside: | 50.09% upside | 52.91% upside | 23.46% upside | 11.18% downside |
Corcept Therapeutics (NASDAQ:CORT) Consensus Price Target History
Corcept Therapeutics (NASDAQ:CORT) Analyst Ratings History
Show:
(Data available from 4/22/2016 forward)
Corcept Therapeutics (NASDAQ:CORT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Corcept Therapeutics (NASDAQ CORT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 19.20%
Institutional Ownership Percentage: 77.20%
Corcept Therapeutics (NASDAQ CORT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/6/2018 | Robert S Fishman | Insider | Sell | 8,000 | $16.22 | $129,760.00 | 8,000 |  |
| 3/7/2018 | Renee D Gala | Director | Buy | 10,000 | $15.51 | $155,100.00 | 1,000 | |
| 3/7/2018 | Robert S Fishman | Insider | Sell | 8,000 | $15.67 | $125,360.00 | 8,000 | |
| 2/7/2018 | Robert S Fishman | Insider | Sell | 8,000 | $16.60 | $132,800.00 | 8,000 | |
| 1/8/2018 | Robert S Fishman | Insider | Sell | 8,000 | $18.67 | $149,360.00 | 8,000 | |
| 12/8/2017 | Robert S Fishman | Insider | Sell | 8,000 | $16.72 | $133,760.00 | 8,000 | |
| 11/13/2017 | G Leonard Baker Jr | Director | Sell | 30,000 | $17.59 | $527,700.00 | | |
| 7/19/2017 | David L Mahoney | Director | Sell | 23,006 | $12.50 | $287,575.00 | | |
| 7/18/2017 | David L Mahoney | Director | Sell | 6,091 | $12.50 | $76,137.50 | | |
| 7/13/2017 | David L Mahoney | Director | Sell | 6,994 | $12.50 | $87,425.00 | | |
| 7/12/2017 | David L Mahoney | Director | Sell | 6,510 | $12.50 | $81,375.00 | | |
| 5/4/2017 | Gary Charles Robb | CFO | Buy | 5,600 | $9.75 | $54,600.00 | 6,858 | |
| 3/16/2017 | Patrick G. Enright | Director | Sell | 269,955 | $9.94 | $2,683,352.70 | | |
| 3/15/2017 | Patrick G Enright | Director | Sell | 600,000 | $10.15 | $6,090,000.00 | 204,210 | |
| 3/8/2017 | Patrick G Enright | Director | Sell | 750,000 | $9.75 | $7,312,500.00 | 204,210 | |
| 2/27/2017 | Patrick G Enright | Director | Sell | 2,500,000 | $8.81 | $22,025,000.00 | 204,210 | |
| 11/25/2016 | Patrick G Enright | Director | Sell | 36,941 | $9.34 | $345,028.94 | | |
| 11/21/2016 | Patrick G Enright | Director | Sell | 544,100 | $9.56 | $5,201,596.00 | | |
| 11/16/2016 | Patrick G Enright | Director | Sell | 174,847 | $9.55 | $1,669,788.85 | | |
| 11/11/2016 | James N Wilson | Director | Sell | 158,812 | $8.51 | $1,351,490.12 | | |
| 11/11/2016 | Joseph K Belanoff | Insider | Sell | 500,000 | $8.98 | $4,490,000.00 | 2,464,195 | |
| 11/7/2016 | Joseph K Belanoff | CEO | Sell | 500,000 | $8.31 | $4,155,000.00 | 2,257,728 | |
| 5/10/2016 | G Leonard Baker Jr | Director | Buy | 100,000 | $4.88 | $488,000.00 | 721,038 | |
| 1/6/2016 | James N Wilson | Director | Sell | 1,188 | $4.90 | $5,821.20 | | |
| 12/10/2015 | Daniel Bradbury | Director | Sell | 20,000 | $4.85 | $97,000.00 | | |
| 11/24/2015 | Daniel Bradbury | Director | Sell | 40,000 | $5.00 | $200,000.00 | | |
| 11/12/2015 | James N Wilson | Director | Sell | 20,000 | $4.90 | $98,000.00 | | |
| 11/2/2015 | Steven Lo | VP | Sell | 12,500 | $4.00 | $50,000.00 | 12,500 | |
| 10/13/2015 | Steven Lo | VP | Sell | 53,033 | $3.82 | $202,586.06 | | |
| 10/7/2015 | Steven Lo | VP | Sell | 5,300 | $4.00 | $21,200.00 | 53,033 | |
| 10/6/2015 | Steven Lo | VP | Sell | 50,000 | $3.76 | $188,000.00 | 58,333 | |
| 9/16/2015 | Daniel Bradbury | Director | Sell | 20,000 | $4.96 | $99,200.00 | | |
| 9/1/2015 | James N Wilson | Director | Sell | 10,000 | $4.90 | $49,000.00 | | |
| 8/27/2015 | Daniel Bradbury | Director | Sell | 20,000 | $4.76 | $95,200.00 | | |
| 7/21/2015 | Daniel Bradbury | Director | Sell | 10,000 | $4.98 | $49,800.00 | | |
| 7/20/2015 | Daniel Bradbury | Director | Sell | 10,000 | $5.32 | $53,200.00 | | |
| 7/8/2015 | David L Mahoney | Director | Sell | 33,828 | $5.74 | $194,172.72 | | |
| 7/1/2015 | James N Wilson | Director | Sell | 10,000 | $6.06 | $60,600.00 | | |
| 6/24/2015 | Daniel Bradbury | Director | Sell | 20,000 | $6.75 | $135,000.00 | | |
| 6/23/2015 | Daniel Bradbury | Director | Sell | 10,000 | $6.92 | $69,200.00 | | |
| 6/2/2015 | James N Wilson | Director | Sell | 10,000 | $6.13 | $61,300.00 | | |
| 3/24/2015 | Patrick G Enright | Director | Sell | 1,089,745 | $5.75 | $6,266,033.75 | | |
| 3/19/2015 | Joseph C Cook Jr | Director | Sell | 77,200 | $5.22 | $402,984.00 | | |
| 6/11/2014 | G Leonard Baker Jr | Director | Buy | 103,386 | $2.32 | $239,855.52 | | |
| 5/13/2014 | Joseph Cook, Jr. | Director | Buy | 100,000 | $1.84 | $184,000.00 | 2,040,826 | |
| 5/12/2014 | Daniel Bradbury | Director | Buy | 138,925 | $1.80 | $250,065.00 | | |
| 5/9/2014 | G Leonard Baker, Jr. | Director | Buy | 100,000 | $1.84 | $184,000.00 | 578,389 | |
| 5/2/2014 | Longitude Venture Partners L.P | Director | Sell | 250,000 | $4.11 | $1,027,500.00 | | |
| 4/1/2014 | Patrick Enright | Director | Sell | 250,000 | $4.28 | $1,070,000.00 | | |
| 3/7/2014 | Longitude Venture Partners L.P | Director | Sell | 250,000 | $4.00 | $1,000,000.00 | | |
| 3/14/2013 | Joseph L Turner | Director | Buy | 10,000 | $2.01 | $20,100.00 | | |
| 12/5/2012 | G Leonard Baker Jr | Director | Buy | 87,131 | $1.46 | $127,211.26 | | |
| 11/23/2012 | Daniel Bradbury | Director | Buy | 179,000 | $1.39 | $248,810.00 | | |
| 11/7/2012 | G Leonard Baker Jr | Director | Buy | 300,000 | $1.83 | $549,000.00 | | |
(Data available from 1/1/2013 forward)
Corcept Therapeutics (NASDAQ CORT) News Headlines
| Source: |
|
Corcept Therapeutics (NASDAQ:CORT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Corcept Therapeutics (NASDAQ:CORT) Income Statement, Balance Sheet and Cash Flow Statement
Corcept Therapeutics (NASDAQ CORT) Stock Chart for Sunday, April, 22, 2018
Loading chart…
